GLP-1 regulates gastric emptying and appetite, and GLP-1 RA is currently indicated for treating type 2 diabetes (T2D), obesity, and metabolic syndrome (MS). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.